CD38 and plasma cell myeloma: Together with the CD38-, SLAMF7-, and BCMA-focused platforms, talquetamab contributes to the emerging paradigm of multi-antigen, multi-platform immunotherapy in multiple myeloma, enabling more personalized and strategically layered treatment approaches.